Company intelligence / Profile preview

레티마크

Seoul/Yongsan-gu, Seoul Special City, South Koreakr.linkedin.com ↗

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

레티마크 is developing a blood-based, AI-powered in vitro diagnostic platform aimed at the early detection of age-related macular degeneration. The company is currently working towards commercialization but has not yet reported clinical trial results or commercial launch.

Therapeutic areas: Ophthalmology
Modalities: DeviceDiagnostic platform
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on 레티마크.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 레티마크.

Explore the full profile